Steve Scala
Stock Analyst at TD Cowen
(2.94)
# 588
Out of 5,253 analysts
34
Total ratings
73.68%
Success rate
40.49%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
AbbVie | Maintains: Strong Buy | 195 225 | 175.88 | 27.93% | 11 | Oct 7, 2024 | |
Bristol-Myers Squibb | Maintains: Hold | 53 59 | 59.13 | -0.22% | 3 | Oct 7, 2024 | |
AstraZeneca | Maintains: Strong Buy | 90 95 | 69.66 | 36.38% | 1 | Aug 12, 2024 | |
Merck & Co | Upgrades: Outperform | 125 135 | 97.11 | 39.02% | 1 | Jan 4, 2024 | |
Pfizer | Downgrades: Market Perform | 32 | 26.68 | 19.94% | 1 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 45 40 | n/a | n/a | 4 | Sep 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 430 500 | 806.49 | -38% | 6 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Apr 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 40 | n/a | n/a | 1 | Jun 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 110 105 | 101.96 | 2.98% | 4 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 55 | 31.82 | 72.85% | 1 | Jul 13, 2020 |